81 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Dec 2026
Next term end
70
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2029 · High confidence
Also notable
Ends Mar 2035 · High confidence
Also notable
Ends Sep 2029 · High confidence
Pyridazine Compounds, Compositions and Methods
US 8,367,672
Cited by 23 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Dynamin 2 Inhibitor for the Treatment of Centronuclear Myopathies
US 10,647,986
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents
US 9,051,302
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Feb 2033 · High confidence
Cited by 35 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 6 to 9, 2026 · next Dec 6
- 2 fees due Jan 11 to 28, 2027 · next Jan 11
- 1 fee due Apr 3, 2027The maintenance fee for Methods and Pharmaceutical Compositions for the Prophylactic Treatment of Metastases (US 11,773,163) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Method for Identifying Personalized Therapeutic Strategies for Patients Affected with a Cancer (US 11,823,799) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jun 5 to 29, 2027 · next Jun 5
- 1 fee due Jul 23, 2027The maintenance fee for Supramolecular Gel Supported on Open-Cell Polymer Foam (US 11,879,038) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Fluorescent Compounds of the Boron Thienyldipyrromethene Type, and Their Use (US 10,566,551) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Method for Chiral Resolution and Device Therefor (US 10,597,339) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 2 fees due Oct 19 to 21, 2027 · next Oct 19
- 1 fee due Nov 12, 2027The maintenance fee for Dynamin 2 Inhibitor for the Treatment of Centronuclear Myopathies (US 10,647,986) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 19, 2026
- 1 term has ended since Aug 19, 2026
What they patent
The 5 largest of its 70 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Recombinant DGKK Gene for Fragile X Syndrome Gene Therapy | 2 in force | to Nov 2039 |
| Peptides for Treatment and Prevention of Nonalcoholic Fatty Liver Disease and Fibrosis | 2 in force | to Sep 2039 |
| Oligonucleotide-Functionalized Hydrophobic Polymer Nanoparticles | 2 in force | to Sep 2039 |
| Bromide Source for Use in Treating Autism Spectral Disorder | 2 in force | to Mar 2038 |
| Method for Modifying the Surface Properties of Elastomer Cellular Foams | 2 in force | to Mar 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,676,798 | Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses held by Centre National de la Recherche Scientifique (CNRS), Universite de Strasbourg and Polyplus Transfection In force · High confidence | In force | High confidence | |
| US 8,163,482 | BBS10 Related Diagnostic Methods for Bardet-Biedl Syndrome In force · High confidence | In force | High confidence | |
| US 9,090,648 | Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses held by Centre National de la Recherche Scientifique (CNRS), Universite de Strasbourg and Polyplus Transfection In force · Medium confidence | In force | Medium confidence | |
| US 10,239,856 | Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents In force · Low confidence | In force | Low confidence | |
| US 8,465,920 | Method for Hybridizing Nucleic Acids held by Polyplus Transfection S.A., Centre National de la Recherche Scientifique and Universite de Strasbourg In force · High confidence | In force | High confidence | |
| US 8,067,412 | Macrocyclic Compounds Useful as Inhibitors of Kinases and HSP90 In force · High confidence | In force | High confidence | |
| US 9,051,302 | Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 8,351,123 | Diffractive Head-Up Display Device Provided with a Device for Adjusting the Position of the Virtual Image held by Delphi Technologies, Inc. and Universite de Strasbourg In force · High confidence | In force | High confidence | |
| US 8,476,461 | Dipyrromethene-Boron Hydrophilic Fluorescent Compounds In force · High confidence | In force | High confidence | |
| US 8,367,672 | Pyridazine Compounds, Compositions and Methods In force · High confidence | In force | High confidence |
Also on record, not counted in the 81: 15 patents in force now held by others · 68 patents ended · 42 applications pending · 120 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.